John works on empirical methods and doctrinal aspects of intellectual property and pharmaceutical law, often melding approaches together to answer social and legal questions. His research has been funded by the Novo Nordisk Foundation, the Wellcome Trust and Cancer Research UK, amongst others. John publishes in diverse, high-profile journals, including Nature Biotechnology, International Review of Intellectual Property & Competition Law, and Federal Law Review. Over the past eight years, John has focused on issues surrounding repurposing. He has empirically studied whether extra commercial incentives for repurposing have been effective, and whether clinical trials for repurposing stop when generics are authorised. John is currently studying the different policy approaches from around the world that aim to overcome the challenges faced when repurposing. He also provides advice and consultancy services to governments, companies, law firms and international government agencies such as the World Intellectual Property Office.
